A consensus statement on the use of angiotensin receptor blockers and angiotensin converting enzyme inhibitors in relation to COVID-19 (corona virus disease 2019)

• Published in: New Zealand medical journal Vol. 133; no. 1512; pp. 85 - 87
• Main Author: Talreja, Hari
• Format: Journal Article
• Language: English
• Published: New Zealand Pasifika Medical Association Group (PMAG) 03.04.2020
• Subjects: Angiotensin converting enzyme; Angiotensin Receptor Antagonists - adverse effects; Angiotensin Receptor Antagonists - therapeutic use; Angiotensin-Converting Enzyme Inhibitors - adverse effects; Angiotensin-Converting Enzyme Inhibitors - therapeutic use; Angiotensins; Animals; Betacoronavirus; Cardiac arrhythmia; Cardiology; Clinical trials; Consensus; Coronavirus infections; Coronavirus Infections - complications; Coronaviruses; COVID-19; Diabetes; Diuretics; Enzymes; Epidemics; Heart; Humans; Hypertension; Hypertension - complications; Hypertension - drug therapy; Infections; Inhibitors; Models, Animal; Pandemics; Peptidyl-Dipeptidase A - drug effects; Peptidyl-Dipeptidase A - metabolism; Physiology; Pneumonia; Pneumonia, Viral - complications; Pneumonia, Viral - drug therapy; Pneumonia, Viral - prevention & control; Receptors; SARS-CoV-2; Severe acute respiratory syndrome coronavirus 2; Society; Viral infections; China
• ISSN: 0028-8446; 1175-8716; 1175-8716

Reviews the evidence supporting the hypothesis that patients with coronavirus disease 2019 (COVID-19) who are receiving angiotensin-converting enzyme (ACE) inhibitors or angiotensin receptor blockers (ARB) may beat increased risk for adverse outcomes. Source: National Library of New Zealand Te Puna Matauranga o Aotearoa, licensed by the Department of Internal Affairs for re-use under the Creative Commons Attribution 3.0 New Zealand Licence.